Trial Profile
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary) ; Insulin degludec; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-T1D
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 01 Jan 2024 Results of pooled analysis from PRONTO-T1D and PRONTO-T2D , investigating contributions of changes in fasting plasma glucose (FPG) and postprandial glucose (PPG) to changes in hemoglobin A1c (HbA1c) and time-in-range (TIR, 70-180 mg/dL) in people with type 1 diabetes , published in the Journal of Diabetes and its Complications
- 29 Jun 2021 Results for the mealtime groups presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 25 Sep 2020 Results of subgroup analysis assessing effect of stratification factors and baseline postprandial glucose on glycaemic control presented at the 56th Annual Meeting of the European Association for the Study of Diabetes